217RO Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2+ early breast cancer: The TRAIN-4 study

ESMO Open 2026 Open access

Read full text
Authors: F.M. Louis, A. van der Voort, MS van Ramshorst, A. Daletzakis, M. Heuver, M.B. Kurstjens-van der Spek, I. Kemper, J. Wesseling, H. Horlings, A. Scholten, M-J.T.F.D. Vrancken Peeters, R. M. Mann
+2 more A. Ommen-Nijhof, G.S. Sonke
DOI: 10.1016/j.esmoop.2026.107171
Cited by: 1

Fields of Study & Subjects

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Cancer Treatment and Pharmacology

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
107171–107171
Publication date
1 May 2026
Language
EN